2020 ASCO Virtual Direct™ Highlights


 

2020 ASCO Update on Recurrent Ovarian Cancer: Does the Addition of Mirvetuximab Soravtansine (MIRV) to Bevacizumab Have Promising Activity in FRα Platinum Agnostic Disease?

64 views
August 18, 2020
0 Comments
Login to view comments. Click here to Login